Evaluation of 18fluorodeoxyglucose positron emission tomography (18FDG PET) in the detection of malignant peripheral nerve sheath tumours arising from within plexiform neurofibromas in neurofibromatosis 1

Ferner, Robin E; Lucas, Jonathan; O’Doherty, Michael; Hughes, Richard A.; Smith, Michael A.; Cronin, B.; Bingham, John

doi:10.1136/jnnp.68.3.353

Cited by 211 publications

(100 citation statements)

References 9 publications

(3 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The utility of positron emission tomography (PET) of ‰uoro-deoxyglucose (FDG) was noted to diŠerentiate MPNST from benign neurogenic tumors in patients with NF 1 because FDG uptake is higher in MPNST than in benign neuroˆbroma. 11 However, the reported standard uptake value (SUV) of MPNST varied, and a higher SUV was found in a benign neuroˆbroma. 12 Scintigraphy and PET scanners are much less available than MR scanners in hospitals, and their scanning times are usually longer than those of MR scanners.…”

Section: Discussionmentioning

confidence: 99%

Diffusion-weighted Imaging of Retroperitoneal Malignant Peripheral Nerve Sheath Tumor in a Patient with Neurofibromatosis Type 1

et al. 2008

View full text Add to dashboard Cite

We present the diŠusion-weighted imaging (DWI)ˆndings for a malignant peripheral nerve sheath tumor arising in a retroperitoneal plexiform neuroˆbroma in a patient with neuroˆbromatosis type 1. Signal intensity of the malignant area was high on DWI and low on the apparent diŠusion coe‹cient map and diŠered fromˆndings for the benign area. DWI enabled clear diŠerentiation between malignant and benign areas of the tumor.

show abstract

Section: Discussionmentioning

confidence: 99%

Diffusion-weighted Imaging of Retroperitoneal Malignant Peripheral Nerve Sheath Tumor in a Patient with Neurofibromatosis Type 1

et al. 2008

View full text Add to dashboard Cite

show abstract

“…The reason is indeterminate: it might be owing to the intrinsic limitation of planar 201 TlCl, to the low-grade malignancy of the tumour or to the small size of the malignant component. Recent articles have suggested the potential contribution of 18-fluorodeoxyglucose positron emission tomography to distinguish MPNST from neurofibroma, even within a single tumour [15,16].…”

Section: Discussionmentioning

confidence: 99%

Early-stage malignant peripheral nerve sheath tumour arising from a solitary neurofibroma

Hyodo¹,

Sugawara²,

Sakayama³

et al. 2012

BJR

View full text Add to dashboard Cite

ABSTRACT. We report a case of early-stage malignant peripheral nerve sheath tumour (MPNST) found in a solitary neurofibroma, and its CT and MRI findings. A 19-year-old male with no known history of a neurofibromatosis presented with a painless swelling in the left forearm. CT and MRI scans showed a well-circumscribed, intermuscular mass, which was 6.0 cm in diameter and contained a strongly enhanced 1.0 cm nodular structure with surrounding oedema. Peripheral nerve continuity with the mass was not seen. Histological evaluation proved the nodular structure was an MPNST component completely surrounded by neurofibroma. Following an excisional biopsy with wide margins, the patient was followed up for a year without treatment and no recurrence was observed.

show abstract

“…Gallium scanning has been reported as being useful in the detection of MPNST in one study [30], but the utility of this approach has not been confirmed. Ferner et al [31] have used (18)fluorodeoxygluocose positron emission tomography to detect MPNST. Increased uptake was found to be characteristic of MPNST, but there was overlap between some benign plexiform neurofibromas and MPNST.…”

Section: Mpnstmentioning

confidence: 99%

Pathophysiology of Neurofibromatosis Type 1

2006

View full text Add to dashboard Cite

Neurofibromatosis type 1 (NF1) represents a major risk factor for development of malignancy, particularly malignant peripheral nerve sheath tumors (MPNST), optic gliomas, other gliomas, and leukemias. The oncologist will see NF1 patients referred for treatment of malignancy, and should be alert to the possibility of undiagnosed NF1 among patients with cancer. Brain tumors tend to have a more indolent course in NF1 than in the general population, and hence are best managed conservatively. MPNST, in contrast, do not respond to standard chemotherapy or radiation therapy. The most effective treatment of MPNST appears to be early diagnosis and surgery, but early diagnosis is hampered by frequent occurrence within preexisting large tumors, making new growth or change difficult to detect. New insights into pathogenesis now offer hope of development of specific methods of treatment with reduced toxicity and more precise molecular targeting. There is an urgent need, however, to develop methods to measure tumor growth and monitor outcomes, develop preclinical drug screening systems, and further explore the pathogenesis of the disorder to determine whether mechanisms other than Ras regulation may be important in pathogenesis.

show abstract

Evaluation of 18fluorodeoxyglucose positron emission tomography (18FDG PET) in the detection of malignant peripheral nerve sheath tumours arising from within plexiform neurofibromas in neurofibromatosis 1

Cited by 211 publications

References 9 publications

Diffusion-weighted Imaging of Retroperitoneal Malignant Peripheral Nerve Sheath Tumor in a Patient with Neurofibromatosis Type 1

Diffusion-weighted Imaging of Retroperitoneal Malignant Peripheral Nerve Sheath Tumor in a Patient with Neurofibromatosis Type 1

Early-stage malignant peripheral nerve sheath tumour arising from a solitary neurofibroma

Pathophysiology of Neurofibromatosis Type 1

Contact Info

Product

Resources

About